Director, Vascular and Interventional Radiology
Director, Interventional Radiology Center, Johns Hopkins Hospital
Professor of Radiology, Surgery and Oncology
Johns Hopkins University School of Medicine
Jeff Geschwind, M.D., is Director of Cardiovascular and Interventional Radiology and Interventional Radiology Research at the Johns Hopkins University School of Medicine.
A native of France, Dr. Geschwind received his medical degree from Boston University School of Medicine in 1991. He completed his residency training in diagnostic radiology at the University of California at San Francisco (UCSF) in 1996, where his research focused on cardiac magnetic resonance (MR) imaging. Dr. Geschwind completed his training in cardiovascular and interventional radiology at Johns Hopkins and joined the faculty in 1998 as an assistant professor. In 2002, he was appointed Division Director of Cardiovascular and Interventional Radiology and in 2008 Director of the Interventional Radiology Center. In 2007, he was promoted to Professor.
As a Johns Hopkins faculty member, Dr. Geschwind has focused his clinical expertise on treating hepatic cancer and other malignancies, and created the Center of Oncologic Interventions. Radiology’s focus is rapidly shifting from diagnosis to image-guided treatment and Jeff Geschwind is at the forefront of that change. Focused on finding new therapies for liver cancer, Dr. Geschwind and his colleagues have been working on a new approach using drugs designed to specifically block tumor metabolism in cancer cells. This research is partially funded through an RO1 grant to Dr. Geschwind from the National Institutes of Health/National Cancer Institute. In 2008, he received a $1.4 million donation to support his research in this field. Dr. Geschwind and colleagues have also continued to improve current therapies for patient with liver cancer, such as chemoembolization. Chemoembolization, the catheter-driven treatment, kills liver tumors by delivering highly concentrated chemotherapeutic drugs directly to the tumor site. At the same time, doctors use tiny "microspheres" as emboli – blocking agents – to temporarily prevent the tumor from getting its full blood supply. Because it is localized, chemoembolization is also much easier on patients than systemic chemotherapy because it directly targets the tumor while preserving healthy tissue.
Dr. Geschwind has authored or co-authored more than 250 published scientific articles and abstracts on interventional oncology specifically the treatment of liver cancer. In the fall of 2008, Dr. Geschwind along with Michael Soulen co-authored the first book dedicated to interventional oncology titled Interventional Oncology Principles and Practice. He has won numerous national grants and international awards, including the Alexander Margulis Society Excellence in Research Award from UCSF in 1995, the Annual Memorial Award from the Association of University Radiologists in 1994 and the Dr. Gary J. Becker Young Investigator Award from the Society of Interventional Radiologists in 2000. In addition, he was named American Roentgen Ray Society Scholar in 2001, which allowed him to pursue a master’s program in molecular biology at Johns Hopkins, and he received the society's 2003 Certificate of Merit. More recently, he was awarded the Merit Award from the American Society of Clinical Oncology for pioneering work in the field of drug delivery. Dr. Geschwind is on the Editorial Board of four journals including the two main interventional radiology journals, the Journal of Vascular and Interventional Radiology and Cardiovascular and Interventional Radiology. Dr. Geschwind also serves on the Advisory Board of various companies including Bayer, Biosphere Medical, Biocompatibles and Philips Medical Systems. He is an active member of the American Society of Clinical Oncology, the American Association for Cancer Research, the Eastern Cooperative Oncology Group, the Radiology Society of North America, the Society of Interventional Radiology, the American Roentgen Ray Society, the Association of University Radiologists and the Cardiovascular and Interventional Society of Europe.
See also:
Liver chemoembolization
